Eiger Biopharmaceuticals Garners $7,100,000 Series A Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=317f5e1c-2973-46e5-b80d-1e361e7b0b91&Preview=1
Date 2/24/2009
Company Name Eiger Biopharmaceuticals
Mailing Address 3350 West Bayshore Road Palo Alto, CA 94303
Company Description Eiger BioPharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger’s pipeline includes repurposed clinical agents as well as preclinical new chemical entities (NCEs) from its discovery research shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
Proceeds Purposes The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.